About the Author
DAVID J. MATTHEWS is Executive Director of OncologyDiscovery at Exelixis, where he is responsible for cancer drugdiscovery. For more than fifteen years, Dr. Matthews has beeninvolved in drug discovery projects in industry, with particularfocus on small molecule inhibitors. He has twenty scientificpublications and multiple patents to his credit. MARY E. GERRITSEN is Vice President of Molecular andCellular Pharmacology at Exelixis, where she is in charge ofcell-based screening in preclinical research and of biomarkerstudies for clinical development compounds in Phase I and IIstudies. Her prior industry experience includes positions atGenentech, Bayer and Millennium Pharmaceuticals. She has authoredmore than one hundred peer-reviewed articles and twenty-six bookchapters and is an inventor on forty-two issued patents.